Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Urelumab |
Trade Name | |
Synonyms | BMS-663513|BMS663513|BMS 663513 |
Drug Descriptions |
Urelumab (BMS-663513) is an activating monoclonal antibody that targets CD137, resulting in activation of CD137-expressing immune cells, thereby enhancing T-cell mediated response to tumor cells (PMID: 31143521, PMID: 32052473). |
DrugClasses | TNFRSF9 Antibody 32 |
CAS Registry Number | 934823-49-1 |
NCIT ID | C62449 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cetuximab + Urelumab | Cetuximab Urelumab | 0 | 1 |
Nivolumab + Urelumab | Nivolumab Urelumab | 0 | 5 |
Relatlimab + Urelumab | Relatlimab Urelumab | 0 | 0 |
Rituximab + Urelumab | Rituximab Urelumab | 0 | 0 |
Urelumab | Urelumab | 0 | 4 |